Aberdeen Group plc Has $6.12 Million Position in NeoGenomics, Inc. $NEO

Aberdeen Group plc boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 91.8% in the third quarter, Holdings Channel reports. The firm owned 792,263 shares of the medical research company’s stock after purchasing an additional 379,165 shares during the period. Aberdeen Group plc’s holdings in NeoGenomics were worth $6,116,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in NEO. Royal Bank of Canada grew its stake in NeoGenomics by 51.2% in the first quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock valued at $532,000 after acquiring an additional 18,966 shares during the period. AQR Capital Management LLC bought a new stake in NeoGenomics in the 1st quarter valued at $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of NeoGenomics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock valued at $719,000 after purchasing an additional 3,254 shares during the period. Intech Investment Management LLC grew its holdings in shares of NeoGenomics by 19.7% during the first quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock worth $1,441,000 after buying an additional 24,965 shares in the last quarter. Finally, CWM LLC boosted its position in NeoGenomics by 118.9% during the 2nd quarter. CWM LLC now owns 13,787 shares of the medical research company’s stock worth $101,000 after acquiring an additional 7,488 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Insider Activity at NeoGenomics

In related news, COO Warren Stone sold 22,128 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the sale, the chief operating officer owned 121,631 shares in the company, valued at approximately $1,520,387.50. This trade represents a 15.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the sale, the executive vice president owned 31,083 shares of the company’s stock, valued at $372,996. The trade was a 40.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.40% of the company’s stock.

NeoGenomics Trading Down 1.2%

Shares of NASDAQ:NEO opened at $9.89 on Friday. The stock has a market cap of $1.28 billion, a PE ratio of -11.77 and a beta of 1.58. The business has a 50 day moving average of $12.06 and a 200-day moving average of $10.14. The company has a quick ratio of 3.62, a current ratio of 4.26 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 12-month low of $4.72 and a 12-month high of $13.74.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 EPS. As a group, equities research analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Benchmark reiterated a “hold” rating on shares of NeoGenomics in a research note on Wednesday. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Needham & Company LLC boosted their price target on NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Finally, Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, NeoGenomics has an average rating of “Hold” and an average target price of $11.57.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.